Unable to maintain a $50 million market value, Marlborough-based Exact Sciences Corp. is in danger of being delisted from the Nasdaq stock market.
The company, which is developing cancer screening technology, received a delisting notice from the Nasdaq earlier this week. Exact said it will request a hearing before the Nasdaq listing qualifications panel. The hearing would postpone the delisting of the company’s stock until the panel comes to a decision.
Without the hearing, Exact would be delisted Aug. 21.
The company reported a second quarter net loss of $2.1 million and a revenue loss of $146,000.
